Work

In Reply to “Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer”

Year: 2023

Type: letter

Abstract: This letter to the editor responds to comments by Sartor et al regarding recent findings on the clinical relevance of CDK12 pathogenic mutations.

Source: The Oncologist

DOI: 10.1093/oncolo/oyad264

Authors: Luca F Valle, Nicholas G Nickols, Kosj Yamoah, Isla P Garraway, Kara N Maxwell, Julie A Lynch

Institutions: University of California, Los Angeles, VA Greater Los Angeles Healthcare System, UCLA Jonsson Comprehensive Cancer Center, Moffitt Cancer Center, James A. Haley Veterans' Hospital, Philadelphia VA Medical Center, Abramson Cancer Center, University of Pennsylvania, University of Utah, University of Massachusetts Boston, VA Salt Lake City Healthcare System

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,494

Funders: U.S. Department of Defense, U.S. Department of Veterans Affairs, Prostate Cancer Foundation, Stop Cancer, Bristol-Myers Squibb, University of Pennsylvania, Jean Perkins Foundation, National Institutes of Health, National Cancer Institute

Awards: G1509237661, G2596546878, G3139259563, G3187070489, G4033677647, G4119534169, G5573458931, G5796888462, G5850682332, G6489053047, G7529533568, G7622722772, G8508340473, CHARACTERIZE THE IMMUNE-ONCOLOGIC PROFILE OF LETHAL PROSTATE CANCER IN AFRICAN AMERICAN MEN AND DEVELOP NEW THERAPEUTIC AVENUES FOR THIS PATIENT POPULATION, G864096937, G9000146483, G9000274547

OpenAlex ID: W4386725856

Cites: 3

Cited by: 3

Related to: 10